Should You Invest in Invitae Right Now?

Genetic testing company Invitae (NYSE: NVTA) has seen its shares tumble from their highs despite aggressively ramping up its test volumes this year. The company is at the center of integrating genetics into healthcare, and this space still has so much potential.

However, sometimes a good story doesn't make for a good investment idea. Investors could buy the dip on Invitae, but they shouldn't ignore a major hang-up on its business model. Here is what you need to know.

Invitae generates revenue by administering genetic tests while steadily also building a genome information database over time. The more tests it administers, the larger and deeper its data is, which it can eventually leverage to create new opportunities to help patients and generate new revenue streams.

Source Fool.com